medigraphic.com
Instituto Nacional de Salud Pública

2021, Number 2

<< Back Next >>

salud publica mex 2021; 63 (2)

Sequential prioritization for vaccination against SARS-CoV-2 in the Mexican population. Preliminary recommendations

Grupo Técnico Asesor de Vacunación Covid-19

Language: Spanish
References: 33
Page: 286-307
PDF size: 748.38 Kb.


ABSTRACT

The supply of the first Covid-19 vaccines to be registered for population use worldwide will be limited in the short and medium term and therefore it is necessary to define population groups that will receive the vaccine initially and subsequently. To this end, Mexico’s Covid-19 Vaccine Technical Advisory Group has reviewed the documents generated by the WHO and various countries on prioritizing population groups to be vaccinated, including the ethical principles and values in the allocation of these vaccines. The preliminary results of vaccination analysis in relation to the risk of dying from Covid-19 in Mexico identified the greatest benefit of vaccination in prioritizing initially health workers and people aged 60 years or older with or without comorbidities descending every decade of life, in addition to people aged 50 to 59 years with comorbidities. Subsequently, to continue the vaccination in the remaining population. In the presence of a public health crisis, the Covid-19 vaccination strategy would be different from the usual mechanisms of the Universal Vaccination Program. The communication of the Covid-19 vaccination strategy must carry a message to reach and understanding of all, which is transparent about the prioritization criteria adopted, and respectful of the essential principles of equity, universality and the common good.


REFERENCES

  1. World Health Organization. Coronavirus disease (Covid-19) pandemic [citado agosto 2020]. Disponible en: from https://www.who.int/emergencies/ diseases/novel-coronavirus-2019

  2. World Health Organization. WHO Coronavirus Disease (Covid-19) Dashboard [citado noviembre 17, 2020]. Disponible en: https://covid19.who.int

  3. Observatorio Covid-19 en América Latina y el Caribe. Impacto Económico y social. Santiago de Chile: Comisión Económica para América Latina y el Caribe/Naciones Unidas [citado noviembre 10, 2020]. Disponible en: https://www.cepal.org/es/temas/covid-19

  4. Socio-economic impact. UN’s Framework for the Immediate Socio- Economic Response to the Covid 19 Crisis [citado noviembre 10, 2020]. Disponible en: https://www.undp.org/content/undp/en/home/coronavirus/ socio-economic-impact-of-covid-19.html

  5. Covid-19 in Latin America: a humanitarian crisis. The Lancet. 2020;(395) https://doi.org/10.1016/S0140-6736(20)32328-X

  6. Poland GA, Ovsyannikova G, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet. 2020;(396). https://doi.org/10.1016/S0140-6736(20)32137-1

  7. WHO SAGE values framework for the allocation and prioritization of Covid-19 vaccination, 14 September 2020. Ginebra: Organización Mundial de la Salud, 2020 [citado noviembre 12, 2020]. Disponible en: https://apps. who.int/iris/handle/10665/334299

  8. Pfizer and BioNTech announce vaccine candidate against Covid-19 achieved success in first interim analysis from phase 3 study [citado noviembre 10, 2020]. Disponible en: https://www.pfizer.com/news/ press-release/press-release-detail/pfizer-and-biontech-announce-vaccinecandidate- against

  9. Moderna’s Covid-19 Vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study [citado noviembre 17, 2020]. Disponible en: https://investors.modernatx.com/ news-releases/news-release-details/modernas-covid-19-vaccine-candidatemeets- its-primary-efficacy/

  10. The first interim data analysis of the Sputnik V vaccine against Covid- 19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy. Instituto Gamaleya press realease [citado noviembre 11, 2020]. Disponible en: https://www.sciencemag.org/sites/default/files/The%20 first%20interim%20data%20analysis%20of%20the%20Sputnik%20V%20 vaccine%20against%20Covid-19%20phase%20III%20clinical%20trials%20 in%20the%20Russian%20Federation%20demonstrated%2092%25%20 efficacy%20.pdf

  11. Interim framework for Covid-19 vaccine allocation and distribution in the United States. Baltimore, MD: Center for Health Security, Johns Hopkins, Bloomberg School of Public Health, 2020 [citado noviembre 11, 2020]. Disponible en: https://www.centerforhealthsecurity.org/our-work/ pubs_archive/pubs-pdfs/2020/200819-vaccine-allocation.pdf

  12. WHO SAGE roadmap for prioritizing uses of Covid-19 vaccines in the context of limited supply. An approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios [citado octubre 26, 2020]. Disponible en: https://www.who.int/ docs/default-source/immunization/sage/covid/sage-prioritization-roadmapcovid19- vaccines.pdf?Status=Temp&sfvrsn=bf227443_2&ua=1

  13. Interim Framework for Covid-19 Vaccine Allocation and Distribution in the United States. Baltimore, MD: Center for Health Security, Johns Hopkins, Bloomberg School of Public Health, 2020 [citado septiembre 4, 2020]. Disponible en: https://www.centerforhealthsecurity.org/our-work/ publications/interim-framework-for-covid-19-vaccine-allocation-anddistribution- in-the-us

  14. Strategic Advisory Group of Experts on Immunization (SAGE). Ginebra: Organización Mundial de la Salud [citado noviembre 10, 2020]. Disponible en: https://www.who.int/groups/strategic-advisory-group-ofexperts- on-immunization/

  15. Immunization, Vaccines and Biologicals. SAGE Working Group on Covid- 19 vaccines. Ginebra: OMS, Organización Mundial de la Salud [citado noviembre 10, 2020]. Disponible en: https://www.who.int/immunization/ sage/sage_wg_covid-19/en/

  16. National Academies of Sciences, Engineering, and Medicine. Framework for Equitable Allocation of COVID-19 Vaccine. Washington, DC: The National Academies Press, 2020. https://doi.org/10.17226/25917

  17. Schleicher A. The impact of Covid-19 on education insights from education at a glance. OECD 2020 [citado octubre 26, 2020]. Disponible en: https://www.oecd.org/education/the-impact-of-covid-19-on-educationinsights- education-at-a-glance-2020.pdf

  18. Clemens V, Deschamps P, Fegert JM, Anagnostopoulos DM, Bailey S, Doyle M, et al. Potential effects of “social” distancing measures and school lockdown on child and adolescent mental health. Eur Child Adolesc Psychiatry. 2020. 29:739-42. https://doi.org/10.1007/s00787-020-01549-w

  19. Goh KK, Lu ML, Jou S. Impact of Covid-19 pandemic: Social distancing and the vulnerability to domestic violence. Psychiatry Clin Neurosci. 2020;74:602-31. https://doi.org/10.1111/pcn.13130

  20. Paces J, Strizova Z, Smrz D, Cerny J. Covid-19 and the Immune System. Physiol Res. 2020;69: 379-88, 2020. https://doi.org/10.33549/physiolres. 934492

  21. Grifoni A, Weiskopf D, Ramirez SI, Smith DM, Crotty S, Sette S. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489-501. https://doi.org/10.1016/j.cell.2020.05.015

  22. World Health Organization. Draft landscape of Covid-19 candidate vaccines [citado noviembre 12, 2020]. Disponible en: https://www.who.int/ publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

  23. William M. Detmer MD, supported by the Unbound Medicine Team. Coronavirus COVID-19 Vaccines [citado noviembre 12, 2020. Disponible en https://relief.unboundmedicine.com/relief/view/Coronavirus-Guidelines/ 2355056/all/Coronavirus_COVID_19_Vaccines

  24. Riel DV, Wit ED. Next-generation vaccine platforms for Covid-19. Nature Materials. 2020;19:810-20. https://doi.org/10.1038/s41563-020-0746-0

  25. Peter G, Myers M. National Vaccine Advisory Committee. National Vaccine Program Office. Intussusception, rotavirus, oral vaccines: summary of a workshop. Pediatrics. 2002;110:67. https://doi.org/10.1542/ peds.110.6.e67

  26. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-205. https://doi.org/10.1056/NEJMoa1506223

  27. The COVAX facility. Global procurement for Covid-19 vaccines [citado septiembre 24, 2020]. Disponible en: https://www.who.int/ publications/m/item/the-covax-facility

  28. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)32318-7

  29. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad Y, et al. Model-informed Covid-19 vaccine prioritization strategies by age and serostatus [preprint]. medRxiv. 2020. https://doi.org/10.1101/2020.09.08. 20190629

  30. Independent Report JCVI: updated interim advice on priority groups for Covid-19 vaccination. United Kingdom: Department of Health and Social Care [citado septiembre 27, 2020]. Disponible en: https://www.gov. uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination- advice-from-the-jcvi-25-september-2020/jcvi-updated-interimadvice- on-priority-groups-for-covid-19-vaccination

  31. World Health Organization. Working together for health. The world health report 2006. Health workers: a global profile, Chapter 1. Geneva: World Health Organization; 2006. Disponible en https://www.who.int/ whr/2006/chapter1/en/

  32. ¿Cuáles son los trabajos esenciales que pueden seguir en la crisis sanitaria? El Economista; 3 de agosto de 2020 [citado septiembre 27, 2020]. Disponible en: https://factorcapitalhumano.com/leyes-y-gobierno/ cuales-son-los-trabajos-esenciales-que-pueden-seguir-en-la-crisis-sanitaria/ 2020/03/

  33. World health Organization. Guidance on developing a national deployment and vaccination plan for Covid-19 vaccines. Interim Guidence, Ginebra: WHO, 2020. Disponible en: https://www.who.int/publications/i/ item/WHO-2019-nCoV-Vaccine_deployment-2020




2020     |     www.medigraphic.com